<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Mental illness &amp;amp; stress.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Work Loss Data Institute. Mental illness &amp; stress. Encinitas (CA): Work Loss Data Institute; 2013 Nov 18. Various p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Work Loss Data Institute. Mental illness &amp;amp; stress. Encinitas (CA): Work Loss Data Institute; 2011. Various p.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Administration of psychologic test  (94.02); Behavior therapy  (94.33); Hypnotherapy  (94.32); Major depressive affective disorder, recurrent episode, unspecified  (296.30); Major depressive affective disorder, single episode, unspecified  (296.20); Music therapy  (93.84); Posttraumatic stress disorder  (309.81); Unspecified acute reaction to stress  (308.9); Unspecified mental or behavioral problem  (V40.9)"/><FieldValue Value="MSH: Acceptance and Commitment Therapy ; Acupuncture Therapy ; Adaptation, Psychological ; Antidepressive Agents ; Aromatherapy ; Behavior Therapy ; Bibliotherapy ; Bupropion ; Causality ; Citalopram ; Cognitive Therapy ; Depression ; Depressive Disorder, Major ; Disease Management ; Drug Delivery Systems ; Electric Stimulation Therapy ; Electroconvulsive Therapy ; Employment, Supported ; Exercise ; Eye Movement Desensitization Reprocessing ; Fish Oils ; Fluoxetine ; Hospitalization ; Hypericum ; Hypnosis ; Kava ; Massage ; Medication Therapy Management ; Melatonin ; Mental Disorders ; MMPI ; Music Therapy ; Narcotic Antagonists ; Occupational Diseases ; Occupational Health ; Panic Disorder ; Patient Education as Topic ; Peer Group ; Phototherapy ; Psychological Tests ; Psychotherapy ; Psychotherapy, Group ; Psychotherapy, Psychodynamic ; Return to Work ; Serotonin Uptake Inhibitors ; Sertraline ; Sickness Impact Profile ; Social Support ; Stress Disorders, Post-Traumatic ; Stress Disorders, Traumatic, Acute ; Stress, Psychological ; Telemedicine ; Therapy, Computer-Assisted ; Thiophenes ; Trazodone ; Virtual Reality Exposure Therapy ; Yoga "/><FieldValue Value="MTH: Acupuncture procedure ; Antidepressive Agents ; Aromatherapy ; Beck depression inventory ; Bupropion ; Cognitive Therapy ; Depression screen ; Disease Management ; Distraction therapy ; Drug Delivery Systems ; Electric Stimulation Therapy ; Electroconvulsive Therapy ; Encounter due to mental and behavioral problems ; Etiology ; Exercise ; Fish Oils ; Group Psychotherapy ; Hospitalization ; Hypericum ; Hypericum perforatum ; Hypnotherapy ; Kava ; MAJOR DEPRESSIVE DISORDER ; Massage ; Melatonin ; Mental Depression ; Mental disorders ; Narcotic Antagonists ; occupational health specialty ; Pain scale ; Panic Disorder ; Patient education (procedure) ; Phototherapy ; Post-Traumatic Stress Disorder ; Psychological adjustment ; Psychological Tests (procedure) ; Psychotherapy ; Serotonin Uptake Inhibitors ; Social support ; Stress, Psychological ; Telemedicine ; Yoga "/><FieldValue Value="PDQ: acupuncture ; aromatherapy ; fluoxetine ; hypnosis ; melatonin ; music therapy ; phototherapy ; post-traumatic stress disorder ; sertraline ; yoga "/><FieldValue Value="SNOMEDCT_US: Acupuncture  (44868003); Acute stress disorder  (67195008); Antidepressant  (36236003); Antidepressant  (372720008); Aromatherapy  (394615007); Assessment using McGill pain questionnaire  (446009008); Beck depression inventory  (273306008); Behavioral therapy  (166001); Bibliotherapy  (386526006); Bupropion  (387564004); Bupropion  (96199001); Citalopram  (321986007); Citalopram  (372596005); Cognitive therapy  (183383008); Cognitive therapy  (228553007); Cognitive therapy  (228557008); Cognitive therapy  (304891004); Depression screening  (171207006); Dialectical behavior therapy  (405780009); Distraction  (414039005); Duloxetine  (407032004); Duloxetine  (407033009); Electroconvulsive therapy  (23835007); Escitalopram  (395246009); Escitalopram  (400447003); Etiology  (134198009); Exercise  (183301007); Exercise  (256235009); Exercise  (61686008); Exposure - behavior therapy  (225224008); Fish oils  (346441008); Fit to return to work  (302120006); Fluoxetine  (372767007); Fluoxetine  (53640004); Group psychotherapy  (76168009); Hypericum  (40499002); Hypericum perforatum  (51621002); Hypnotherapy  (183408002); Hypnotherapy  (19997007); Inpatient care  (394656005); Light therapy  (31394004); Major depressive disorder  (370143000); Melatonin  (116523008); Melatonin  (41199001); Mental disorder  (74732009); Minnesota multiphasic personality inventory  (44575007); Music therapy  (21065008); Occupational disorder  (115966001); Opiate antagonist  (14103001); Opiate antagonist  (372656001); Panic disorder  (371631005); Patient education  (311401005); Piper methysticum  (8880009); Posttraumatic stress disorder  (47505003); Psychodynamic psychotherapy  (314034001); Psychologic test  (1999007); Psychological assessment  (405783006); Psychological assessment  (45392008); Psychotherapy  (75516001); Recurrent major depressive episodes  (268621008); Recurrent major depressive episodes  (66344007); Returned to work  (266962006); Sertraline  (321958004); Sertraline  (372594008); Sickness impact profile  (273807008); Single major depressive episode  (268620009); Single major depressive episode  (36923009); Spiritual support  (385728004); Spiritual support  (385988005); Spiritual support  (386444001); Stress management  (226060000); Stress management  (441151000124104); Therapeutic electrical stimulation  (169430000); Therapeutic electrical stimulation  (57942008); Trazodone  (372829000); Trazodone  (7336002)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Work-related stress, major depressive disorder, post-traumatic stress disorder, and other mental disorders&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Counseling" /><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Family Practice" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Psychiatry" /><FieldValue Value="Psychology" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Health Care Providers" /><FieldValue Value="Health Plans" /><FieldValue Value="Nurses" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /><FieldValue Value="Psychologists/Non-physician Behavioral Health Clinicians" /><FieldValue Value="Social Workers" /><FieldValue Value="Utilization Management" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To offer evidence-based step-by-step decision protocols for the assessment and treatment of workers' compensation conditions&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Workers with occupational stress, major depressive disorder, and other mental disorders&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following interventions/procedures were considered and recommended as indicated in the original guideline document:&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Acceptance and commitment therapy (ACT) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Acupuncture &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Antidepressants, for treatment of:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Major depressive disorder (MDD) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Post-traumatic stress disorder (PTSD) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Aromatherapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Brief Battery for Health Improvement &amp;ndash; 2nd edition (BBHI&amp;trade; 2) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Beck Depression Inventory &amp;ndash; 2nd edition (BDI &amp;reg; - II) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Battery for Health Improvement &amp;ndash; 2nd edition (BHI&amp;trade; 2) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Bibliotherapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Brief Symptom Inventory (BSI&amp;reg;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Brief Symptom Inventory-18 (BSI&amp;reg; 18) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Bupropion (Wellbutrin&amp;reg;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Causality (determination) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cognitive therapy for:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Amputation &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Depression &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Opioid dependence &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Panic disorder &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;PTSD &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;General stress &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cognitive behavioral stress management (CBSM) to reduce injury and illness &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Computer-assisted cognitive therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Depression screening &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Desvenlafaxine (Pristiq) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Dialectical behavior therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Disease management (programs) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Distractive methods (to reduce acute stress) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Duloxetine (Cymbalta&amp;reg;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Electroconvulsive therapy (ECT) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Escitalopram (Lexapro&amp;reg;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Exercise &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Expatriate employee adjustment support &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Exposure therapy (ET) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Eye movement desensitization and reprocessing (EMDR) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Fish oil &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Fluoxetine (Prozac&amp;reg;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Group therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hospital length of stay (LOS) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hypnosis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Imagery rehearsal therapy (IRT) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Insomnia treatment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Kava extract (for anxiety) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Light therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;MDD (mild, moderate, severe, and psychotic presentations)&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Diagnosis &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Initial treatment &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Massage therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Millon Behavioral Medical Diagnostic (MBMD&amp;trade;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;McGill Pain Questionnaire (MPQ)/McGill Pain Questionnaire - Short Form (MPQ-SF) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Melatonin &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mind/body interventions (for stress relief) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Minnesota Multiphasic Personality Inventory (MMPI) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Minnesota Inventory &amp;ndash; 2nd edition&amp;trade; (MMPI-2&amp;trade;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Multidimensional Pain Inventory (MPI) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Music (for relaxation/stress management) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Office visits &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Opioid antagonists (especially naltrexone) for alcohol dependence &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Optimism (and its effect on schema-focused therapy) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patient education (to reduce stress related to illness) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Peer support (for postpartum depression) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Psychodynamic psychotherapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Psychological evaluations for patients prior to undergoing intrathecal drug delivery systems (IDDS) and spinal cord stimulators (SCS) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Psychosocial adjunctive methods (for PTSD) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Psychotherapy for:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;MDD &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;PTSD &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;PTSD pharmacotherapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Return to work &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Selective serotonin reuptake inhibitors (SSRIs) for PTSD &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Sertraline (Zoloft&amp;reg;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;SF 36&amp;trade; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Sickness Impact Profile (SIP) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Spiritual support &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;St. John's wort (for depression) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Stress inoculation training &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Stress management, behavioral/cognitive and physical (interventions) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Telephone cognitive behavioral therapy (CBT) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Trazodone (Desyrel) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Virtual reality (VR) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Weaning of medications (antidepressants) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Work/activity restrictions &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Yoga &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;The following interventions/procedures are under study and are not specifically recommended:&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Acupressure &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Antidepressants &amp;ndash; SSRIs versus tricyclic antidepressants (TCAs) as first-line treatment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Brain wave synchronizers (for stress reduction) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Depression, effect on:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Heart health &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The gene factor &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Folate (for depressive disorders) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Magneto-encephalography (MEG) for PTSD &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Psychosocial/pharmacological treatments (for deliberate self harm) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reiki &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;S-adenosylmethionine (SAMe) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Sentra PM&amp;trade; for insomnia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Stress and:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Atherosclerosis (effect) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Blood pressure (effect) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Depression (effect) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Physiology/mental performance (effect) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Heart-related interventions &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Tension headaches (pharmaceuticals vs. behavioral therapy) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Therapeutic touch (TT) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Transcranial magnetic stimulation (TMS) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Vitamin B6 for depression &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Vitamin B12 for impaired cognitive function and depression &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Vitamin use (for stress reduction) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;The following interventions/procedures were considered, but are not recommended:&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Atypical antipsychotics as a first-line treatment (including aripiprazole [Abilify], olanzapine [Zyprexa], quetiapine [Seroquel], risperidone [Risperdal]) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Behavioral Assessment of Pain-2 (BAP-2) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Center for Epidemiological Studies Depression Scale (CES-D) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Millon Behavioral Health Inventory (MBHI&amp;trade;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Millon Clinical Multiaxial Inventory, 3rd edition (MCMI-111&amp;trade;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Nuedexta &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Oswestry Disability Questionnaire (ODI) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pain Patient Profile (P-3&amp;trade;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pain Assessment Battery (PAB) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patient Health Questionnaire (PHQ) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Post Traumatic Stress Diagnostic Scale (PDS&amp;trade;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Personality Assessment Inventory (PAI&amp;trade;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pain Presentation Inventory (PPI) &amp;nbsp; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Primary Care Evaluation for Mental Disorders (PRIME-MD) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Psychological debriefing (for preventing post-traumatic stress disorder) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Symptom Checklist-90 Revised (SCL-90-R&amp;reg;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Stress &amp;amp; cancer (effect) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Vagus nerve stimulation (VNS) for depression &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Vilazodone (Viibryd&amp;reg;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Visual Analogue Pain Scale (VAS) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Zolpidem &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Zung Depression Inventory &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Effectiveness of treatments in reducing stress, anxiety, and depressive symptoms &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adverse effects of treatments &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Hand-searches of Published Literature (Primary Sources)" /><FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" /><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Work Loss Data Institute (WLDI) conducted a comprehensive medical literature review (now ongoing) with preference given to high quality systematic reviews, meta-analyses, and clinical trials published since 1993, plus existing nationally recognized treatment guidelines from the leading specialty societies. WLDI primarily searched MEDLINE and the Cochrane Library. In addition, WLDI also reviewed other relevant treatment guidelines, including those in the National Guideline Clearinghouse, as well as state guidelines and proprietary guidelines maintained in the WLDI guideline library. These guidelines were also used to suggest references or search terms that may otherwise have been missed. In addition, WLDI also searched other databases, including MD Consult, eMedicine, CINAHL, and conference proceedings in occupational health (i.e., American College of Occupational and Environmental Medicine [ACOEM]) and disability evaluation (i.e., American Academy of Disability Evaluating Physicians [AADEP], American Board of Independent Medical Examiners [ABIME]). Search terms and questions were diagnosis, treatment, symptom, sign, and/or body-part driven, generated based on new or previously indexed existing evidence, treatment parameters and experience.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In searching the medical literature, answers to the following questions were sought: (1) If the diagnostic criteria for a given condition have changed since 1993, what are the new diagnostic criteria? (2) What occupational exposures or activities are associated causally with the condition? (3) What are the most effective methods and approaches for the early identification and diagnosis of the condition? (4) What historical information, clinical examination findings or ancillary test results (such as laboratory or x-ray studies) are of value in determining whether a condition was caused by the patient's employment? (5) What are the most effective methods and approaches for treating the condition? (6) What are the specific indications, if any, for surgery as a means of treating the condition? (7) What are the relative benefits and harms of the various surgical and non-surgical interventions that may be used to treat the condition? (8) What is the relationship, if any, between a patient's age, gender, socioeconomic status and/or racial or ethnic grouping and specific treatment outcomes for the condition? (9) What instruments or techniques, if any, accurately assess functional limitations in an individual with the condition? (10) What is the natural history of the disorder? (11) Prior to treatment, what are the typical functional limitations for an individual with the condition? (12) Following treatment, what are the typical functional limitations for an individual with the condition? (13) Following treatment, what are the most cost-effective methods for preventing the recurrence of signs or symptoms of the condition, and how does this vary depending upon patient-specific matters such as underlying health problems?&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Criteria for Selecting the Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Preference was given to evidence that met the following criteria: (1) The article was written in the English language, and the article had any of the following attributes: (2) It was a systematic review of the relevant medical literature, or (3) The article reported a controlled trial &amp;ndash; randomized or controlled, or (4) The article reports a cohort study, whether prospective or retrospective, or (5) The article reports a case control series involving at least 25 subjects, in which the assessment of outcome was determined by a person or entity independent from the persons or institution that performed the intervention the outcome of which is being assessed.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;More information about the selection of evidence is available in &quot;Appendix B. &lt;em&gt;ODG Treatment in Workers' Comp&lt;/em&gt;. Methodology description using the AGREE instrument&quot; (see the &quot;Availability of Companion Documents&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Ranking by Type of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Systematic Review/Meta-Analysis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Controlled Trial - Randomized (RCT) or Controlled &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cohort Study - Prospective or Retrospective &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Case Control Series &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Unstructured Review &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Nationally Recognized Treatment Guideline (from &lt;a href=&quot;http://www.guideline.gov&quot; title=&quot;NGC Web site&quot; target=&quot;_blank&quot;&gt;www.guideline.gov&lt;/a&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;State Treatment Guideline &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Other Treatment Guideline &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Textbook &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Conference Proceedings/Presentation Slides &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Ranking by Quality within Type of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;    &lt;li&gt;High Quality &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Medium Quality &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Low Quality &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Work Loss Data Institute (WLDI) reviewed each article that was relevant to answering the question at issue, with priority given to those that met the following criteria: (1) The article was written in the English language, and the article had any of the following attributes: (2) It was a systematic review of the relevant medical literature, or (3) The article reported a controlled trial &amp;ndash; randomized or controlled, or (4) The article reported a cohort study, whether prospective or retrospective, or (5) The article reported a case control series involving at least 25 subjects, in which the assessment of outcome was determined by a person or entity independent from the persons or institution that performed the intervention the outcome of which is being assessed.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Especially when articles on a specific topic that met the above criteria were limited in number and quality, WLDI also reviewed other articles that did not meet the above criteria, but all evidence was ranked alphanumerically (see the &quot;Rating Scheme for the Strength of the Evidence&quot; field) so that the quality of evidence could be clearly determined when making decisions about what to recommend in the Guidelines. Articles with a Ranking by Type of Evidence of Case Reports and Case Series were not used in the evidence base for the Guidelines. These articles were not included because of their low quality (i.e., they tend to be anecdotal descriptions of what happened with no attempt to control for variables that might affect outcome). Not all the evidence provided by WLDI was eventually listed in the bibliography of the published Guidelines. Only the higher quality references were listed. The criteria for inclusion was a final ranking of 1a to 4b (the original inclusion criteria suggested the methodology subgroup), or if the Ranking by Type of Evidence was 5 to 10, the quality ranking should be an &quot;a.&quot;&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Not stated" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guideline developers reviewed published cost analyses.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Prior to publication, select organizations and individuals making up a cross-section of medical specialties and typical end-users externally reviewed the guideline. Complimentary review access is also made available to all major medical specialty groups as well as other stakeholders.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;em&gt;Note from the Work Loss Data Institute (WLDI) and the National Guideline Clearinghouse (NGC)&lt;/em&gt;&lt;/strong&gt;: The following recommendations were current as of November 18, 2013. However, because the Work Loss Data Institute updates their guidelines frequently, users may wish to consult the &lt;a href=&quot;http://www.disabilitydurations.com/&quot; title=&quot;WLDI Web site&quot;&gt;WLDI Web site&lt;/a&gt; for the most current version available.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Refer to the original guideline document for the outline of treatment planning and introductory discussion of claims of mental illness within workers compensation.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Major Depressive Disorder&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Major Depressive Disorder (MDD), Definition&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The American Psychiatric Association's diagnostic manual (&lt;em&gt;American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition &amp;ndash; Text Revision&lt;/em&gt;) defines MDD as a mental illness that is characterized by one or more major depressive episodes without a history of manic, mixed, or hypomanic episodes (some details that will help to provide an understanding of what this definition means are provided below). This mental illness is typically manifested in phases &amp;ndash; the person is mentally ill for a period of time, and is then typically free from the symptoms of the mental illness for a period of time, but will probably develop additional episodes of symptoms in the future.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The &quot;major depressive episodes&quot; to which the above definition refers are the phases when the symptoms are present. These episodes are defined as: (1) a period of at least 2 weeks during which there is either depressed mood or the loss of interest or pleasure in nearly all activities; (2) the individual also experiences at least four additional symptoms drawn from a list that includes changes in appetite or weight, sleep disturbance, psychomotor agitation or psychomotor retardation, decreased energy, feelings of worthlessness or guilt, difficulty thinking/concentrating/making decisions, recurrent thoughts of death or suicidal ideation/plans/attempts; and (3) the symptoms must persist for most of the day, nearly every day, for at least 2 consecutive weeks.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The portion of the definition which reads &quot;without a history of manic, mixed, or hypomanic episodes&quot; serves to separate major depressive disorder from the bipolar and cyclothymic disorders.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Major Depressive Disorder, Diagnosis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The essential core of the diagnostic evaluation is the protocol provided in the American Psychiatric Association's diagnostic manual. The diagnostician should compare the claimant's presentation to all of the information in that protocol, including diagnostic features, associated features and disorders, course, and differential diagnosis.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The following examples of issues from that protocol are not intended to serve as a substitute for the full protocol. These examples are only being provided in order to give readers some idea of what the protocol involves, and to at least partially convey the complex nature of the protocol.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;MDD is characterized by a history of one or more major depressive episodes. These episodes are phases when the symptoms are present for most of the day, nearly every day, for at least 2 consecutive weeks.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Diagnostic features for such major depressive episodes include:&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;A period of at least 2 weeks during which there is:&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;        &lt;li&gt;A depressed mood, and/or &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The loss of interest or pleasure in nearly all activities &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;At least &lt;strong&gt;four&lt;/strong&gt; additional symptoms drawn from a list that includes:&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Changes in appetite or weight &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Sleep disturbance &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Psychomotor agitation (e.g., observable restlessness) or psychomotor retardation (e.g., observably moving more slowly than usual) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Decreased energy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Feelings of worthlessness or guilt &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Difficulty thinking/concentrating/making decisions &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Recurrent thoughts of death or suicidal ideation/plans/attempts &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Course&lt;/em&gt;: This mental illness is typically manifested in phases &amp;ndash; the person is mentally ill for a period of time, and is then typically free from the symptoms of the mental illness for a period of time, but will probably develop additional episodes of symptoms in the future.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Differential Diagnosis&lt;/em&gt;: The person with this disorder has not experienced any manic, mixed, or hypomanic episodes (which would push the diagnosis toward the bipolar and cyclothymic disorders, instead of MDD). The symptoms cannot be attributed to any other mental illness, or to any general medical condition.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Psychological Tests&lt;/em&gt; (e.g., current editions of the Minnesota Multiphasic Personality Inventory, Battery for Health Improvement, Millon Clinical Multiaxial Inventory, Structured Interview of Reported Symptoms) can be used as an important adjunct to the diagnostic process, specifically for the purpose of introducing an objective element to a process that is otherwise completely subjective.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Thorough Review of Claimant's History&lt;/em&gt; can ideally involve an examination of records from the claimant's entire life, and collateral reports. This thorough type of approach is preferable to relying on the report of the claimant, because scientific findings have consistently revealed that an examinee's report of his or her history is not a credible basis for clinical decision-making.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Any such diagnostic evaluation (and associated treatment planning) should take place on an independent basis. If the evaluation does not take place on an independent basis, then the clinician must avoid any discussion regarding forensic issues such as work-relatedness, disability, etc.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Stress&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Initial Evaluation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Focus on identifying possible red flags or warning signs for potentially serious psychopathology that would require immediate specialty referral. Red flags may include impairment of mental functions, overwhelming symptoms, signs of substance abuse, or debilitating depression. In the absence of red flags, the occupational or primary care physician can handle most common stress-related conditions safely.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In talking to the patient, it is important for the physician to get him or her to try and explain or pinpoint incidents or reasons for the stress, rather than to just generalize (i.e., &quot;I hate my job,&quot; &quot;Everything makes me stressed out,&quot; etc.). The physician may have to ask more specific questions about work or home life if the patient is initially unwilling or unable to address specific issues.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Occupational stress usually stems from one of three common models:&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Person-environment fit model&lt;/em&gt;: Poor job fit, such as a mismatch between the skills of the individual and the demands of the job, or a disparity between the individual's career-related desires vs. actual opportunities presented, is a leading cause of workplace stress. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Demand control model&lt;/em&gt;: Jobs that place high demands on the worker but give him or her little control or opportunities for decision-making lead to high job strain, a source of stress that is consistently linked as a contributor to physical conditions such as cardiovascular mortality, heart disease, and hypertension. Consideration should be given to the influence of the individual's occupational and personal history, which may have an effect on how this model applies to his or her situation. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Effort-reward model&lt;/em&gt;: Shows that stress is often the result of high effort without social reward. Like the demand control model, this model points out that a low ratio of effort to reward leads to sustained autonomic arousal and can cause physical effects such as high blood pressure or myocardial infarction. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;Exploration of how and if the patient's stress follows the path of one of the above models will be helpful in determining treatment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;More specific sources of stress include bereavement, illness, familial changes or disorder, or other common and/or traumatic life changes. Time off work may be helpful, although the ultimate goal should be to preserve the patient's ability to function both occupationally and socially. Time off should not be so excessive that the employee loses his or her sense of function and appreciation at work and at home.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Initial Therapy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Pursuing the patient's thoughts on how his or her stress relates to the above models may help determine the source of stress and cultivate ideas on how to eliminate or cope with the stress. Patient education and understanding about stress is necessary for effective stress management to take place. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Other common treatment pathways include the use of one or more of the following:&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Relaxation techniques (such as meditation) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Exercise (aerobic exercise has been shown to positively influence mood) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Behavioral training (such as time management, anger management, assertiveness, or conflict resolution training) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Stress inoculation therapy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Cognitive therapy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Modified work &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Organizational interventions &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pharmaceutical therapy (limited, short-term use of anti-anxiety agents to improve function&amp;mdash;anything else should be used in conjunction with a specialty referral) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;Follow-up visits are an important part of treatment and should be conducted by a mid-level practitioner in person or via phone every three or four days, depending on the severity of the case, while a path to recognizable treatment is established and followed. Failure to improve or make significant progress after several months may indicate the need for psychiatric assessment or counseling.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Post-traumatic Stress Disorder (PTSD)&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The concept of PTSD was created by the American Psychiatric Association in 1980 to serve as a diagnosis for presentations of mental illness by people who have experienced an &quot;extreme traumatic stressor.&quot; According to the current version of the American Psychiatric Association's diagnostic manual, the diagnosis of PTSD involves at least nine elements, which are outlined below: (1) The person witnessed death, a threat of death, or physical danger; (2) The person responded to that experience with intense fear, helplessness, or horror; (3) The person has symptoms which involve &quot;re-experiencing&quot; item #1 (example: repeating memories of item #1, with those memories being perceived as intrusive, and with those memories causing distress); (4) The person demonstrates avoidance of things that remind them of item #1; (5) The person experiences a &quot;numbing of general responsiveness&quot; (example: the person is unable to have loving feelings); (6) The person experiences symptoms of &quot;increased arousal&quot; (example: difficulty falling or staying asleep); (7) The involved distress or impairment is &quot;clinically significant&quot;; (8) The symptoms typically begin within the first three months after item #1, and typically resolve within a few months of onset; (9) The symptoms last for more than a month after item #1.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Refer to the original guideline document for Summary Tables for PTSD pharmacotherapy and PTSD psychotherapy interventions.&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Official Disability Guidelines (ODG) Return-To-Work Pathways&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;Official Disability Guidelines (ODG) Return-To-Work Pathways&lt;/strong&gt; &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            &lt;strong&gt;Senile and Presenile Organic Psychotic Conditions&lt;/strong&gt; (see original guideline document for International Classification of Diseases, Ninth Revision [ICD-9] codes for this and other diagnoses)&#xD;&#xA;            &lt;p&gt;Not severe, medical treatment: 0 days&lt;br /&gt;&#xD;&#xA;            Severe, specially designed, limited modified work: 7 days&lt;br /&gt;&#xD;&#xA;            Severe, regular work: indefinite&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Senile Dementia with Delusional or Depressive Features&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;Severe, specially designed, limited modified work: 7 days&lt;br /&gt;&#xD;&#xA;            Severe, affecting fellow worker productivity &amp;amp; safety: indefinite&lt;br /&gt;&#xD;&#xA;            Severe, regular work: indefinite&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Alcohol Withdrawal Delirium&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;Without hospitalization: 1 to 7 days&lt;br /&gt;&#xD;&#xA;            Including rehab, substance abuse professional (SAP) evaluation: 28 days&lt;br /&gt;&#xD;&#xA;            Including rehab, SAP evaluation, job safety issues: 42 days&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Drug Withdrawal Syndrome&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;Without hospitalization: 0 to 5 days&lt;br /&gt;&#xD;&#xA;            With hospitalization, without suicidal ideation: 7 days&lt;br /&gt;&#xD;&#xA;            With hospitalization, with suicidal ideation: 21 days&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Paranoid and/or Hallucinatory States Induced by Drugs&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;Without hospitalization: 1 to 3 days&lt;br /&gt;&#xD;&#xA;            With hospitalization, without threat of harm: 7 days&lt;br /&gt;&#xD;&#xA;            With hospitalization, with threat of harm: 21 days&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Transient Organic Psychotic Conditions&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;14 days&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Paranoid Type&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;Without hospitalization, no job safety issues: 0 to 7 days&lt;br /&gt;&#xD;&#xA;            With hospitalization: 42 days or by report&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Unspecified Schizophrenia&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;Without hospitalization, no job safety issues: 0 to 7 days&lt;br /&gt;&#xD;&#xA;            With hospitalization: 16 to 42 days&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Major Depressive Disorder, Single Episode&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;Rule out impaired mood/personality disorder: 0 days&lt;br /&gt;&#xD;&#xA;            Outpatient therapy, without symptoms affecting work: 0 to 7 days&lt;br /&gt;&#xD;&#xA;            Outpatient therapy, with symptoms interfering with work: 21 to 42 days&lt;br /&gt;&#xD;&#xA;            With hospitalization, non-cognitive/modified work: 21 days&lt;br /&gt;&#xD;&#xA;            With hospitalization, cognitive work: 42 days&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Major Depressive Disorder, Recurrent Episode&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;Outpatient therapy, without symptoms affecting work: 0 to 7 days&lt;br /&gt;&#xD;&#xA;            Outpatient therapy, with symptoms interfering with work: 14 to 28 days&lt;br /&gt;&#xD;&#xA;            With hospitalization, non-cognitive/modified work: 21 days&lt;br /&gt;&#xD;&#xA;            With hospitalization, cognitive work: 42 days&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Bipolar Affective Disorder, Depressed&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;Rule out impaired mood/personality disorder: 0 days&lt;br /&gt;&#xD;&#xA;            Without hospitalization: 0 to 21 days&lt;br /&gt;&#xD;&#xA;            With hospitalization: 21 to 42 days&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Bipolar Affective Disorder, Mixed&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;Without hospitalization: 0 to 14 days&lt;br /&gt;&#xD;&#xA;            With hospitalization: 21 to 42 days&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Paranoia&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;Without hospitalization: 0 to 14 days&lt;br /&gt;&#xD;&#xA;            With hospitalization: 14 to 21 days&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Depressive Type Psychosis&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;Without hospitalization: 0 to 56 days&lt;br /&gt;&#xD;&#xA;            With hospitalization: 21 to 64 days&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Anxiety States&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;Rule out impaired mood/personality disorder: 0 days&lt;br /&gt;&#xD;&#xA;            Without hospitalization: 0 to 7 days&lt;br /&gt;&#xD;&#xA;            With hospitalization: 14 to 21 days&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Panic Disorder&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;1 to 14 days&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Generalized Anxiety Disorder&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;14 to 21 days&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Hysteria&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;Without hospitalization: 0 days&lt;br /&gt;&#xD;&#xA;            With hospitalization: 7 to 14 days&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Obsessive-Compulsive Disorders&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;Without hospitalization: 0 days&lt;br /&gt;&#xD;&#xA;            With hospitalization: 10 days&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Personality Disorders&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;0 days&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Alcohol Dependence Syndrome&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;Without hospitalization: 1 day&lt;br /&gt;&#xD;&#xA;            Without hospitalization, considering fellow worker danger and morale: 7 to 14 days&lt;br /&gt;&#xD;&#xA;            With hospitalization, including rehab: 14 to 28 days&lt;br /&gt;&#xD;&#xA;            Safety sensitive position: as determined by the SAP&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Acute Alcoholic Intoxication&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;1 to 2 days&lt;br /&gt;&#xD;&#xA;            Also treated as rule violation absence&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Opioid Type Dependence&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;Without hospitalization: 0 days&lt;br /&gt;&#xD;&#xA;            Without hospitalization, considering fellow worker danger and morale: 7 to 14 days&lt;br /&gt;&#xD;&#xA;            With hospitalization, including rehab: 14 to 38 days (10 days post-discharge)&lt;br /&gt;&#xD;&#xA;            Safety sensitive position: as determined by the SAP&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Barbiturate and Similarly Acting Sedative or Hypnotic Dependence&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;Without hospitalization: 0 days&lt;br /&gt;&#xD;&#xA;            Without hospitalization, considering fellow worker danger and morale: 7 to 14 days&lt;br /&gt;&#xD;&#xA;            With hospitalization: 21 days&lt;br /&gt;&#xD;&#xA;            With hospitalization, plus rehab: 28 days&lt;br /&gt;&#xD;&#xA;            Safety sensitive position: as determined by the SAP&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Cocaine Dependence&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;Without hospitalization: 0 days&lt;br /&gt;&#xD;&#xA;            Without hospitalization, considering fellow worker danger and morale: 7 to 14 days&lt;br /&gt;&#xD;&#xA;            With hospitalization: 28 days&lt;br /&gt;&#xD;&#xA;            Safety sensitive position: as determined by the SAP&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Cannabis Dependence&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;0 to 2 days&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Amphetamine and Other Psychostimulant Dependence&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;Without hospitalization: 0 days&lt;br /&gt;&#xD;&#xA;            Without hospitalization, considering fellow worker danger and morale: 7 to 14 days&lt;br /&gt;&#xD;&#xA;            With hospitalization: 14 days&lt;br /&gt;&#xD;&#xA;            With hospitalization, plus rehab: 28 days&lt;br /&gt;&#xD;&#xA;            Safety sensitive position: as determined by the SAP&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Hallucinogen Dependence&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;Without hospitalization: 0 days&lt;br /&gt;&#xD;&#xA;            Without hospitalization, considering fellow worker danger and morale: 7 to 14 days&lt;br /&gt;&#xD;&#xA;            With hospitalization: 10 days&lt;br /&gt;&#xD;&#xA;            With hospitalization, plus rehab: 28 days&lt;br /&gt;&#xD;&#xA;            Safety sensitive position: as determined by the SAP&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Alcohol Abuse&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;1 day&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Cocaine Abuse&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;Without hospitalization: 0 to 1 days&lt;br /&gt;&#xD;&#xA;            With hospitalization: 10 days&lt;br /&gt;&#xD;&#xA;            With hospitalization, plus rehab: 28 days&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Amphetamine or Related Acting Sympathomimetic Abuse&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;Without hospitalization: 1 day&lt;br /&gt;&#xD;&#xA;            With hospitalization: 14 days&lt;br /&gt;&#xD;&#xA;            With hospitalization, plus rehab: 28 days&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Acute Reaction to Stress&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;Without hospitalization (on-going counseling/drug therapy): 1 day&lt;br /&gt;&#xD;&#xA;            With hospitalization: 10 days&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Unspecified Acute Reaction to Stress, Post-traumatic Stress Disorder&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;Without hospitalization (on-going counseling): 1 day&lt;br /&gt;&#xD;&#xA;            With hospitalization: 10 days&lt;br /&gt;&#xD;&#xA;            Chemical dependence comorbidity: 28 days&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Adjustment Reaction&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;Without hospitalization: 1 to 6 days&lt;br /&gt;&#xD;&#xA;            Outpatient care: 1 to 6 days&lt;br /&gt;&#xD;&#xA;            With inpatient hospitalization: 14 to 28 days&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Post-concussion Syndrome&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;Mild: 1 day&lt;br /&gt;&#xD;&#xA;            Severe: by report&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Depressive Disorder, not Elsewhere Classified&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;Rule out impaired mood/personality disorder: 0 days&lt;br /&gt;&#xD;&#xA;            Outpatient therapy, without symptoms affecting work or other job issues: 0 to 7 days&lt;br /&gt;&#xD;&#xA;            Outpatient therapy, with symptoms interfering with work: 21 days&lt;br /&gt;&#xD;&#xA;            Outpatient therapy, with serious job satisfaction issues: 28 to 42 days&lt;br /&gt;&#xD;&#xA;            With hospitalization, non-cognitive/modified work: 28 days&lt;br /&gt;&#xD;&#xA;            With hospitalization, cognitive work: 42 to 56 days&lt;/p&gt;&#xD;&#xA;            &lt;strong&gt;Attention Deficit Disorder&lt;/strong&gt;&#xD;&#xA;            &lt;p&gt;1 day&lt;/p&gt;&#xD;&#xA;            (See &lt;em&gt;ODG Capabilities &amp;amp; Activity Modifications for Restricted Work&lt;/em&gt; under &quot;Work&quot; in the Procedure Summary in the original guideline document) &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;During the comprehensive medical literature review, preference was given to high quality systematic reviews, meta-analyses, and clinical trials over the past ten years, plus existing nationally recognized treatment guidelines from the leading specialty societies.&lt;/p&gt;&#xA;&lt;p&gt;The heart of each Work Loss Data Institute guideline is the Procedure Summary (see the original guideline document), which provides a concise synopsis of effectiveness, if any, of each treatment method based on existing medical evidence. Each summary and subsequent recommendation is hyper-linked into the studies on which they are based, in abstract form, which have been ranked, highlighted and indexed.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;These guidelines unite evidence-based protocols for medical treatment with normative expectations for disability duration. They also bridge the interests of the many professional groups involved in diagnosing and treating work-related stress, major depressive disorder, and other mental disorders.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;From a clinical point of view the analysis of antidepressants' safety profile (adverse effect and suicide risk) remains of crucial importance and more reliable data about these outcomes are needed. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Tricyclic antidepressants (TCAs) are among the most effective antidepressants available, although their poor tolerance at usual recommended doses and toxicity in overdose make them difficult to use. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;While selective serotonin reuptake inhibitors (SSRIs) are better tolerated than TCAs, they have their own specific problems, such as the aggravation of sexual dysfunction, interaction with co-administered drugs, and for many, a discontinuation syndrome. Despite the relative low prevalence of side effects associated with SSRIs a significant minority of older people find these drugs intolerable and experience nausea, vomiting, dizziness and drowsiness. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The Beck Depression Inventory-2nd edition (BDI&amp;reg;-II) is limited to assessment of depression and is easily faked. The scale is unable to identify a non-depressed state, and is thus very prone to false positive findings. It should not be used as a stand-alone measure, especially when secondary gain is present. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The risk of suicidal behavior after starting antidepressant treatment is similar among users of amitriptyline (a TCA) and fluoxetine (an SSRI). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Postmarketing reports of hepatic injury (including hepatitis and cholestatic jaundice) suggest that patients with preexisting liver disease who take duloxetine (Cymbalta) may have an increased risk for further liver damage. The new labeling extends the precaution against using Cymbalta in patients with substantial alcohol use to include those patients with chronic liver disease. It is recommended that Cymbalta not be administered to patients with any hepatic insufficiency. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Antidepressant medication (fluoxetine/Prozac) has been found to compromise the success of smoking cessation efforts. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hypomania as a potential adverse effect of light therapy needs to be considered. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Because exposure therapy (ET) may increase distress and post-traumatic stress disorder (PTSD) symptoms in the short term, it is not well accepted by all patients, some of whom may drop out of treatment. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Benzodiazepines are only recommended for short-term use due to risk of tolerance, dependence, and adverse events (daytime drowsiness, anterograde amnesia, next-day sedation, impaired cognition, impaired psychomotor function, and rebound insomnia). These drugs have been associated with sleep-related activities such as sleep driving, cooking and eating food, and making phone calls (all while asleep). Particular concern is noted for patients at risk for abuse or addiction. Withdrawal occurs with abrupt discontinuation or large decreases in dose. Decrease slowly and monitor for withdrawal symptoms. Benzodiazepines are similar in efficacy to benzodiazepine-receptor agonists; however, the less desirable side-effect profile limits their use as a first-line agent, particularly for long-term use. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Piper methysticum&lt;/em&gt; (Kava) has been withdrawn in European, British, and Canadian markets due to concerns over hepatotoxic reactions, and the World Health Organization (WHO) recently recommended research into &quot;aqueous&quot; extracts of Kava. One randomized controlled trial (RCT) concluded that the aqueous Kava preparation produced significant anxiolytic and antidepressant activity and raised no safety concerns. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Due to adverse effects, U.S. Food and Drug Administration (FDA) now requires lower doses for zolpidem. The dose of zolpidem for women should be lowered from 10 mg to 5 mg for immediate release (IR) products and from 12.5 mg to 6.25 mg for extended release (ER) products. The ER product is still more risky than IR. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Side effects of trazodone include nausea, dry mouth, constipation, drowsiness, and headache. Improvements in sleep onset may be offset by negative next-day effects such as ease of awakening. Tolerance may develop and rebound insomnia has been found after discontinuation. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Next-day sedation with diphenhydramine has been noted as well as impaired psychomotor and cognitive function. A randomized controlled study determined that diphenhydramine has been shown to build tolerance against its sedation effectiveness very quickly, with placebo-like results after a third day of use. Due to adverse effects, the U.S. National Committee for Quality Assurance (NCQA) has included diphenhydramine in the HEDIS&amp;reg; (Healthcare Effectiveness Data and Information) recommended list of high-risk medications to avoid in the elderly. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The following are current suggested exclusionary criteria for the use of an implantable pain treatment: (a) Active psychosis; (b) Active suicidal ideation; (c) Active homicidal ideation; (d) Untreated or poorly treated major depression or major mood disturbance. Depression in and of itself in reaction to chronic pain does not disqualify a patient from implantable treatment, although moderately severe to severe depression should be treated prior to trial. Anxiety/panic disorder should also be stabilized; (e) Somatization disorder or other somatoform disorder involving multiple bodily complaints that are unexplained or exceed that could be explained by the physical exam; (f) Alcohol or drug dependence (including drug-seeking behavior and/or uncontrolled escalated use); (g) Lack of appropriate social support; (h) Neurobehavioral cognitive deficits that compromise reasoning, judgment and memory. Other &quot;red flags&quot; include: a) unusual pain ratings (for example, the pain rating never changes from 9-10); b) unstable personality and interpersonal function; c) non-physiological signs reported on physical exam; d) unresolved compensation and litigation issues. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;There are a number of contraindications for using traditional hypnotic techniques in the treatment of post-traumatic stress disorder (PTSD): (1) In the rare cases of individuals who are refractory or minimally responsive to suggestions, hypnotic techniques may not be the best choice, because there is some evidence that hypnotizability is related to treatment outcome efficacy; (2) Some PTSD patients may be reluctant to undergo hypnosis, either because of religious belief or other reasons. If the resistance is not cleared after dispelling mistaken assumptions, other suggestive techniques can be tried, including emotional self-regulation therapy (ESRT), which is done with open eyes and uses sensory recall exercises rather than a hypnotic induction; (3) For patients who have low blood pressure or are prone to fall asleep, hypnotic procedures such as &quot;alert hand,&quot; which emphasize alertness and activity rather than relaxation, may be substituted. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients living in dangerous circumstances (e.g., domestic violence or a threatening environment) are not candidates for exposure therapy until their security can be assured. Other contraindications for exposure therapy have not been confirmed in empirical research, but may include health problems that preclude exposure to intense physiological arousal: current suicidal ideation, substance abuse not in stable remission, co-morbid psychosis, or lack of motivation to undergo the treatment. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Due to adverse effects, the U.S. National Committee for Quality Assurance (NCQA) has included diphenhydramine in the HEDIS&amp;reg; (Healthcare Effectiveness Data and Information) recommended list of high-risk medications to avoid in the elderly. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Psychosocial rehabilitation techniques are contraindicated when client and clinician conclude that the problems are resolved.&lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Morphine is contraindicated in serious traumatic brain injury.&lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Marriage counseling is typically contraindicated in cases of domestic violence, until the batterer has been successfully (individually) rehabilitated. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The Treatment Planning section is not designed to be a rule, and therefore should not be used as a basis for Utilization Review. The Treatment Planning section outlines the most common pathways to recovery, but there is no single approach that is right for every patient and these protocols do not mention every treatment that may be recommended. See the Procedure Summaries (in the original guideline document) for complete lists of the various options that may be available, along with links to the medical evidence. The Procedure Summaries are the most important section of Official Disability Guidelines (ODG) Treatment, and that section, not the Treatment Planning section, should be used as a basis for Utilization Review. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is difficult to establish work-relatedness for major depressive disorder. Individuals who are treated within workers compensation for this disorder may be at an elevated risk of being exposed to the detrimental health effects of involvement in workers' compensation. Scientific findings have indicated that involvement in workers compensation leads to worse clinical outcomes (worse than the outcomes that are obtained when the treatment is delivered outside of the workers compensation system). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The definition of major depressive disorder provided in the guideline is a highly summarized definition that is not intended to provide a full understanding of major depressive disorder. It is instead simply intended to provide readers with a simple overview. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Mobile Device Resources" /><FieldValue Value="Patient Resources" /><FieldValue Value="Staff Training/Competency Material" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Work Loss Data Institute. Mental illness &amp; stress. Encinitas (CA): Work Loss Data Institute; 2013 Nov 18. Various p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2004 (revised 2013 Nov 18)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Work Loss Data Institute - For Profit Organization" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Work Loss Data Institute&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Editor-in-Chief, Philip L. Denniston, Jr., and Senior Medical Editor, Charles W. Kennedy, Jr., MD, together pilot the group of approximately 80 members. See the ODG &lt;em&gt;Treatment in Workers Comp&lt;/em&gt; &lt;a href=&quot;http://www.worklossdata.com/editorial-advisory-board.html&quot; title=&quot;Work Loss Data Institute Web site&quot;&gt;Editorial Advisory Board&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;There are no conflicts of interest among the guideline development members.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Work Loss Data Institute. Mental illness &amp;amp; stress. Encinitas (CA): Work Loss Data Institute; 2011. Various p.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available to subscribers from the &lt;a href=&quot;http://www.odg-disability.com/&quot; title=&quot;Work Loss Data Institute Web site&quot;&gt;Work Loss Data Institute Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from the Work Loss Data Institute, 169 Saxony Road, Suite 210, Encinitas, CA 92024; Phone: 800-488-5548, 760-753-9992, Fax: 760-753-9995; &lt;a href=&quot;http://www.worklossdata.com&quot; title=&quot;Work Loss Data Institute Web site&quot;&gt;www.worklossdata.com&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Background &amp;amp; description. Available to subscribers from the &lt;a href=&quot;http://www.odg-twc.com/&quot; title=&quot;Work Loss Data Institute (WLDI) Web site&quot;&gt;Work Loss Data Institute (WLDI) Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Appendix B. ODG Treatment in Workers' Comp. Methodology description using the AGREE instrument. 2014. Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.worklossdata.com/uploads/2/4/1/6/24166932/odg_agree_2014.pdf&quot; title=&quot;Work Loss Data Institute Web site&quot;&gt;WLDI Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;In addition, self-training modules are available from the &lt;a href=&quot;http://www.worklossdata.com/training.html&quot; title=&quot;Work Loss Data Institute (WLDI) Web site&quot;&gt;WLDI Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;ODG Mobile Pro is available to order from the &lt;a href=&quot;http://www.worklossdata.com/odg-mobile-pro.html&quot; title=&quot;Work Loss Data Institute (WLDI) Web site&quot;&gt;WLDI Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following is available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Appendix C. &lt;em&gt;ODG Treatment in Workers' Comp&lt;/em&gt;. Patient information resources. 2008. Electronic copies: Available to subscribers from the &lt;a href=&quot;http://www.odg-disability.com/&quot; title=&quot;Work Loss Data Institute Web site&quot;&gt;Work Loss Data Institute Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from the Work Loss Data Institute, 169 Saxony Road, Suite 210, Encinitas, CA 92024; Phone: 800-488-5548, 760-753-9992, Fax: 760-753-9995; &lt;a href=&quot;http://www.worklossdata.com&quot; title=&quot;Work Loss Data Institute Web site&quot;&gt;www.worklossdata.com&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Disclaimer&quot;&gt;Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI on April 4, 2005. This summary was updated by ECRI on August 15, 2005, following the U.S. Food and Drug Administration advisory on antidepressant medications. This summary was updated by ECRI on October 20, 2005, following the U.S. Food and Drug Administration advisory on Cymbalta (duloxetine hydrochloride). This NGC summary was updated by ECRI on January 30, 2006, November 13, 2006, April 2, 2007, and August 29, 2007. This summary was updated by ECRI Institute on October 31, 2007, following the U.S. Food and Drug Administration advisory on Antidepressant drugs. This NGC summary was updated by ECRI Institute on January 28, 2009, May 26, 2011, and April 8, 2014.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
